Results 161 to 170 of about 4,719,787 (282)
Students perception towards feedback in clinical sciences in an outcome-based integrated curriculum. [PDF]
Pak J Med Sci, 2018 Ansari T, Usmani A.
europepmc +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Short Communications: Para Clinical Sciences
RUHS Journal of Health Sciences, 2023 Postgraduate Students
doaj +1 more source
Nasal and Pharyngeal Colonization by Bacterial Pathogens: A Comparative Study between Preclinical and Clinical Sciences Medical Students. [PDF]
Can J Infect Dis Med Microbiol, 2018 Bhatta DR +7 more
europepmc +1 more source
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Blueprint for Constructing an AI-Based Patient Simulation to Enhance the Integration of Foundational and Clinical Sciences in Didactic Immunology in a US Doctor of Pharmacy Program: A Step-by-Step Prompt Engineering and Coding Toolkit. [PDF]
Pharmacy (Basel)Malhotra A +4 more
europepmc +1 more source
An elective course on the basic and clinical sciences aspects of vitamins and minerals. [PDF]
Am J Pharm Educ, 2013 Islam MA.
europepmc +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source